PDL BioPharma (PDLI) Posts Q1 EPS of $0.04

PDL BioPharma (NASDAQ: PDLI) reported Q1 GAAP EPS of $0.04, which may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $45.4 million versus the consensus estimate of $50.23 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance